ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical research analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- [Imaging diagnostics for diseases of the small bowel].Radiologie (Heidelberg, Germany) · 2026Review
- The prognostic effect of dualBMC gastroenterology · 2026Article
- Article
- Article
- Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours.EJNMMI research · 2024Article
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy.Cancers · 2023Review
- Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.Cancers · 2023Review
- Review
- Review
- PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.Life (Basel, Switzerland) · 2023Review
- Dual [British journal of cancer · 2023Article
- Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.European journal of radiology open · 2023Article
- Review
- Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Value of [EJNMMI research · 2022Article
- New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.Current treatment options in oncology · 2022Review
- "The past is a different country, they do things differently there": using the SEER data-base to assess prognosis in neuroendocrine tumours.Endocrine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
PET scans using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.